Discover what best-in-class publishing looks like.
Re:GEN Open brings together the dynamic, global media presence of Genetic Engineering & Biotechnology News (GEN) and the scientific peer-reviewed publishing expertise of Mary Ann Liebert, Inc., publishers to deliver an unprecedented publishing experience: best-in-class author services, rapid and credible peer review, and international exposure across the leading media platforms in the industry.
This exciting new open access journal is dedicated to publishing advances across all aspects of basic and translational biomedical research, including regenerative medicine, genetics and genomics, cancer research, drug development, cell and gene therapy, and infectious disease. Original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, and technology reports are welcome.
The only choice for your next manuscript
The things that matter to you are the things that matter to us: speed, credibility, authority, visibility, and discoverability.
Re:GEN Open is the home for your next manuscript.
Rapid, authoritative peer review that is trusted across the industry
Retain copyright of your work with a CC-BY license, the most liberal available
Fully funder compliant, ensuring you meet all grant requirements
Preprints welcome
Exposure to more than 450,000 unique visitors every month across the Mary Ann Liebert, Inc. and GEN websites
Selected articles included in dynamic marketing campaigns to more than 250,000 highly engaged readers
Selected articles promoted via social media to more than 600,000 followers
Global media outreach for selected papers
Translation, editing, and research promotion services available
Submit your manuscript now for rapid publication in Spring 2021
Interested in becoming an editorial board member? Contact editorial@regenopen.com for more information.